Mercado de pruebas farmacogenéticas en psiquiatría y depresión en Asia Pacífico: tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado de pruebas farmacogenéticas en psiquiatría y depresión en Asia Pacífico

Las pruebas farmacogenéticas ayudan a los profesionales médicos al proporcionar información sobre cómo una persona metaboliza un medicamento. Esta información puede ayudar a los médicos y a otras personas a evitar recetar antidepresivos que podrían producir resultados indeseables. La farmacogenómica ha demostrado ser prometedora para predecir la respuesta y la tolerabilidad de los antidepresivos en el tratamiento del trastorno depresivo mayor (TDM). La farmacogenómica puede mejorar los resultados clínicos al orientar la selección y la dosificación de los antidepresivos. El creciente sector de la biotecnología y el aumento del gasto sanitario han acelerado la demanda de pruebas farmacogenéticas en psiquiatría y depresión.

La creciente prevalencia de enfermedades oncológicas, las nuevas tecnologías para el tratamiento de la depresión y otras enfermedades psiquiátricas están aumentando la adopción de dispositivos y procedimientos de pruebas farmacogenéticas en psiquiatría y depresión, y la creciente preferencia por procedimientos no quirúrgicos son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico. Sin embargo, el alto costo asociado con las pruebas, la estricta regulación y la falta de concienciación pueden obstaculizar el crecimiento del mercado de pruebas farmacogenéticas en psiquiatría y depresión en el período de pronóstico.

Data Bridge Market Research analiza que se espera que el mercado de pruebas farmacogenéticas en psiquiatría/depresión de Asia Pacífico alcance un valor de USD 375,42 millones para 2029, con una CAGR del 10,6 % durante el período de pronóstico. La ansiedad representa el segmento de tipo más grande en el mercado debido a la creciente tasa de depresión entre la población de Asia Pacífico. Este informe de mercado también cubre en profundidad el análisis de precios, el análisis de patentes y los avances tecnológicos.

Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market Definition

Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.

The terms personalized medicine, stratified medicine, and precision medicine are close relatives of pharmacogenetics, but these are broader terms that also cover additional non-genetic factors. Nevertheless, pharmacogenetics is an important component of these areas. Pharmacogenetics is primarily concerned with human germline DNA variation, but recent advances have also been made in understanding mood disorders and mental illnesses.

Pharmacogenetics testing studies the interaction between the drug and gene response of a person and searches for the gene variation, which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights which subsequently be used to develop customized or personalized medication.

Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER

Depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Depression can become a serious health condition of mild to extreme severity, affecting the person to suffer greatly and can lead to suicide in the worst cases. Although over 45 antidepressants are available, suboptimal response poses a challenge and is considered a result of genetic variation, psychiatry/depression. Depending on the severity and pattern of depressive episodes over time, healthcare providers may offer psychological diagnosis such as behavioral activation, cognitive behavioral therapy, interpersonal psychotherapy, and/or antidepressant medication such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Different drugs are used for this kind of mental disorder.

With the growth in the prevalence of depression, the demand for pharmacogenetics testing is also increasing as it studies the effect of genetic variants intending to furnish tailored diagnosis. The market is expected to grow in foresting period.

• RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE

Pharmacogenetics test aids the medical professional in choosing the best medicine for the person because the test searches for the gene variant that may be responsible for influencing the effect of the drug.

Medicine is becoming personal, and patients gradually express interest in improved outcomes and less adverse effects with personalized medications. Personalized medicine has the potential to tailor the therapy with a high safety margin and the best response. This trend is largely driven by genome sequencing improvements.

The move toward personal healthcare means changes in the manufacturing of medicines. Manufacturers are moving from creating small molecules to the combination of small molecule and gene therapies. Sponsors focus on replacing inefficient large-scale batch production with investment in new technology and producing personalized drugs.

Restraint

• Lack of skilled medical and genomic expert 

Most clinicians still lack confidence in pharmacogenetic (PGx) testing and subsequent data interpretation, indicating insufficient knowledge in this field. It emphasizes the need to improve literacy among healthcare professionals regarding expertise in the understanding of pharmacogenetic (PGx) testing.

Lack of practitioners awareness about the possibilities of pharmacogenetics and poor or insufficient explanation of the test results also reduce personalization technologies for patients. In addition to developing thematic training courses at medical universities, including the educational cycles in continuing professional education systems and free placement of information for practicing doctors are required: academic internet portals, webinars, etc. A clinical pharmacologist plays a crucial role in the implementation of pharmacogenetic testing.

The competence of a clinical pharmacologist in the field of pharmacogenetics is critical: he or she is the one who organizes the application of genotyping in clinical practice, interprets tests, and informs doctors about the possibilities of pharmacogenetics for patients with specific nosologies that act as the main link between the scientific world, the healthcare system and practicing physicians in the process of introducing pharmacogenetics.

Opportunity

• Rising advancements in technology

Advances in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice for psychiatric disorders. Personalized medicine may be defined as a comprehensive, prospective approach to preventing, diagnosing, treating, and monitoring disease in ways that achieve optimal individual health care decisions. Over 100 medications now contain United States Food and Drug Administration (FDA) labelling related to potentially applicable pharmacogenomic biomarkers with technological advancements in healthcare. Also, new and advanced methods are being developed to promote pharmacogenetics testing in depression-like disorders. These tests use advanced genetic testing methods to give precise results to form a treatment regimen. The improvements in technology supporting tests improved accessibility of testing options, and the growing number of resources that help clinicians understand how to use this information when it is available are making this aspect of personalized or precision medicine a reality. Thus, providers need to become more aware of the scientific and clinical relevance of pharmacogenomic tests.

The tests also help to establish a meaningful relationship between a drug and the individual genetic makeup. This helps in deciding the drugs to be administered to the patient to treat major depressive disorders and other psychiatric conditions.

Challenge

• Strict government regulation on new products and instruments approval

The concerns regarding the efficacy and safety of products have caused most governments to develop regulatory agencies and policies to look after the development of new medical products or tests. The use of these medical products can be done after passing stringent regulatory standards, which ensure the product is safe, well studied, and has no adverse reactions.

The recent guidelines and the amendment have adequate guidance for manufacturers. International regulations such as food, drug, and administration play a major role in the new launch of the medical product or test into the market. Thus, it can be a major restraint for the market. Therefore, strict government regulation on new products and instrument approval will likely impact the market.

Post-COVID-19 Impact on Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market

The COVID-19 outbreak had a beneficial impact on the expansion of the pharmacogenetics testing industry. The pandemic has had a negative impact on the pharmacogenomics market growth on account of the temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers. Since the second half of 2020, with the rising demand for research on certain drugs and testing kits for COVID-19, pharmacogenomic practices have been in vogue.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Developments

• In April 2022, Blue Care Network (BCN) launched a precision medicine program. Blue cross personalized medicine leverages pharmacogenomics, or genetic testing, to personalize and tailor medication treatments more effectively for select members based on a review of their prescribed medications for various diagnosis, including behavioral health, cardiology, cardiovascular, and oncology. OneOme LLC has helped BCN achieve its precision medicine program goals and reduce the total cost of care, and improve patient health outcomes by reducing adverse drug reactions. This has helped the company to enhance its product portfolio.
• In February 2022, PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced that it is supporting The Hospital for Sick Children (SickKids) in Toronto, Canada, in using HiFi whole genome sequencing (HiFi WGS) to potentially identify genetic variants that may be associated with medical and developmental conditions. Samples that are examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology but still lack the identification of a disease-causing variant. This has helped the company to enhance the use of its products.
• In July 2022, according to a new nationwide study of nearly 2,000 veterans conducted by the U.S. Department of Veterans Affairs (VA), and Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight Psychotropic test results from Myriad Genetics, Inc. in largest ever mental health PGx randomized controlled trial. This has helped the company to show its progress in pharmacogenetic testing.
• In January 2021, myDNA Life Australia Pty Ltd announced a merger with the U.S., Houston-based consumer DNA test company, FamilyTreeDNA, and its parent company. Gene by Gene for revolutionizing the field of pharmacogenomics, making truly personalized medicine a reality, before expanding into nutrigenomics to deliver actionable, personalized nutrition, fitness, and skincare recommendations. This has helped the company to expand its business.

 Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market Scope

Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into type, test type, gene type, patient type, product, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Type
  • Anxiety
  • Mood Disorders
  • Depression
  • Bipolar Disorders
  • Psychotic Disorders
• Eating Disorders

On the basis of type, Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders.

• Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Test Type
  • Whole Genome Sequencing
  • Chromosomal Array-Based Tests

On the basis of test type, Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests.

• Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Gene Type
  • CYP2C19
  • CYP2C9 AND VKORC1
  • CYP2D6
  • HLA-B
  • HTR2A/C
  • HLA-A
  • CYP3A4
  • SLC6A4
  • MTHFR
  • COMT
• OTHERS

On the basis of gene type, Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.

• Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Patient Type
  • Child
  • Adult
  • Geriatric

On the basis of patient type, the Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into child, adult, and geriatric.

• Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Product
  • Instruments
  • Consumables
  • Software & Services

On the basis of product type, Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services.

• Asia Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By End User
  • Hospitals & Clinics
  • Dignostics Laboratories
  • Academic And Research Institutes
  • Others

On the basis of end user, Asia Pacific pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others.

• Mercado de pruebas farmacogenéticas en psiquiatría y depresión en Asia Pacífico, por canal de distribución
  • Licitación directa
  • Distribución de terceros
  • Farmacia hospitalaria
  • Otros

Sobre la base del canal de distribución, el mercado de pruebas farmacogenéticas en psiquiatría/depresión de Asia Pacífico está segmentado en licitación directa, distribución de terceros, farmacias hospitalarias y otros.

Análisis y perspectivas regionales del mercado de pruebas farmacogenéticas en psiquiatría y depresión en Asia Pacífico

Se analiza el mercado de pruebas farmacogenéticas de Asia Pacífico en psiquiatría/depresión y se proporciona información sobre el tamaño del mercado por tipo, tipo de prueba, tipo de gen, tipo de paciente, producto, usuario final y canal de distribución.

Los países cubiertos en este informe de mercado son China, Japón, India, Corea del Sur, Singapur, Tailandia, Malasia, Australia, Vietnam, Filipinas, Indonesia y el resto de Asia-Pacífico.

En 2022, Asia Pacífico ocupará el tercer lugar en importancia debido al aumento de las colaboraciones estratégicas y los lanzamientos de los principales actores del mercado. Se espera que Japón crezca debido al aumento de los avances tecnológicos en las pruebas farmacogenéticas.

La sección de países del informe también proporciona factores individuales que impactan en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia Pacífico y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de las pruebas farmacogenéticas en psiquiatría y depresión en Asia Pacífico

El panorama competitivo del mercado de pruebas farmacogenéticas en psiquiatría/depresión de Asia Pacífico proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones, la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado de pruebas farmacogenéticas en psiquiatría/depresión de Asia Pacífico.

Algunos de los principales actores que operan en el mercado de pruebas farmacogenéticas en psiquiatría/depresión de Asia Pacífico son

• Genelex (Parte de la corporación Invitae)
• Genewiz (parte de Azenta Life Sciences)
• Laboratorios MD
• BiogeneiQ, Inc.
• ONEOME, LLC
• Genética Myriad, Inc.
• GenXys
• Biociencias del castillo, inc.
• Biopacífico
• QIAGEN
• Termo Fisher Scientific Inc.
• AB-Biotics, SA 
• Ciencias de la vida de Coriell
• Eurofins Científico
• Ilumina, Inc.
• Laboratorios de ADN dinámico
• STADAPHARM GmbH
• Color
• Dosis de CNS
• Genomind, Inc.
• Saludspek
• Español: myDNA Life Australia Pty Ltd.
• HudsonAlpha
• Atención sanitaria sónica limitada

Metodología de investigación: mercado de pruebas farmacogenéticas en psiquiatría y depresión en Asia Pacífico

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con tamaños de muestra grandes. Los datos del mercado se analizan y estiman utilizando modelos estadísticos y coherentes del mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Aparte de esto, los modelos de datos incluyen la cuadrícula de posicionamiento de proveedores, el análisis de la línea de tiempo del mercado, la descripción general y la guía del mercado, la cuadrícula de posicionamiento de la empresa, el análisis de la participación de mercado de la empresa, los estándares de medición, Asia Pacífico frente a la región y el análisis de la participación de los proveedores. Solicite una llamada de un analista en caso de tener más consultas.

SKU-60336